CEOs from Medtronic, Intuitive Surgical, Boston Scientific and Dexcom were on hand this week in San Francisco to discuss the year ahead at the J.P. Morgan Healthcare Conference.

The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

The global cardiovascular devices market, valued at US$ 72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3% ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

New technologies for atrial fibrillation, hypertension, diabetes and neurological conditions are poised for fast growth, Martha said Monday at the J.P. Morgan Healthcare Conference.

Johnson & Johnson MedTech (NYSE: JNJ) announced that it received CE mark approval for its dual-energy ThermoCool SmartTouch ...

This comprehensive research combines qualitative and quantitative data from primary and secondary sources. It aims to provide an in-depth understanding of the current market scenario and the impact of ...

EP catheters were placed in the morphologic right ... energy using a 4-mm tipped cryoablation catheter (Cryocath, Medtronic Inc., Minneapolis, MN, USA). Cryoablation at this site during AVNRT ...

Kalyanam Shivkumar, MD, PhD (UCLA Health, Los Angeles, CA), editor-in-chief of JACC: Clinical Electrophysiology ... from around the world issued a new expert consensus statement on catheter and ...